TW202146024A - 包含達拉菲尼、erk抑制劑和raf抑制劑或pd-1抑制劑之三重藥物組合 - Google Patents

包含達拉菲尼、erk抑制劑和raf抑制劑或pd-1抑制劑之三重藥物組合 Download PDF

Info

Publication number
TW202146024A
TW202146024A TW110107183A TW110107183A TW202146024A TW 202146024 A TW202146024 A TW 202146024A TW 110107183 A TW110107183 A TW 110107183A TW 110107183 A TW110107183 A TW 110107183A TW 202146024 A TW202146024 A TW 202146024A
Authority
TW
Taiwan
Prior art keywords
cancer
compound
braf
dabrafenib
pharmaceutically acceptable
Prior art date
Application number
TW110107183A
Other languages
English (en)
Chinese (zh)
Inventor
凡瑟莉娜 庫克
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202146024A publication Critical patent/TW202146024A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110107183A 2020-02-28 2021-02-26 包含達拉菲尼、erk抑制劑和raf抑制劑或pd-1抑制劑之三重藥物組合 TW202146024A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062983020P 2020-02-28 2020-02-28
US62/983,020 2020-02-28

Publications (1)

Publication Number Publication Date
TW202146024A true TW202146024A (zh) 2021-12-16

Family

ID=76845267

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110107183A TW202146024A (zh) 2020-02-28 2021-02-26 包含達拉菲尼、erk抑制劑和raf抑制劑或pd-1抑制劑之三重藥物組合

Country Status (9)

Country Link
EP (1) EP4110341A2 (fr)
JP (1) JP2023516155A (fr)
KR (1) KR20220148846A (fr)
CN (1) CN115279374A (fr)
AU (1) AU2021225491A1 (fr)
CA (1) CA3173356A1 (fr)
IL (1) IL295626A (fr)
TW (1) TW202146024A (fr)
WO (1) WO2021171260A2 (fr)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
CA2508660C (fr) 2002-12-23 2013-08-20 Wyeth Anticorps anti pd-1 et utilisations
SI2439273T1 (sl) 2005-05-09 2019-05-31 Ono Pharmaceutical Co., Ltd. Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
JP2012510429A (ja) 2008-08-25 2012-05-10 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよびその使用方法
WO2010029435A1 (fr) 2008-09-12 2010-03-18 Isis Innovation Limited Anticorps spécifiques de pd-1 et leurs utilisations
SI2342226T1 (sl) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
US8993731B2 (en) 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
RU2604814C2 (ru) 2011-07-24 2016-12-10 Кьюртек Лтд. Варианты гуманизированных иммуномодулирующих моноклональных антител
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
PL3702373T3 (pl) 2013-09-13 2022-12-05 Beigene Switzerland Gmbh Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne
HUE039306T2 (hu) 2013-11-01 2018-12-28 Novartis Ag Kináz inhibitor aminoheteroaril-benzamidok
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2018051306A1 (fr) * 2016-09-19 2018-03-22 Novartis Ag Combinaisons thérapeutiques comprenant un inhibiteur de raf et un inhibiteur d'erk
KR20200138303A (ko) * 2018-03-30 2020-12-09 노파르티스 아게 다브라페닙, 트라메티닙 및 erk 저해제를 포함하는 삼중 약제학적 조합물

Also Published As

Publication number Publication date
JP2023516155A (ja) 2023-04-18
WO2021171260A2 (fr) 2021-09-02
EP4110341A2 (fr) 2023-01-04
CA3173356A1 (fr) 2021-09-02
WO2021171260A3 (fr) 2021-10-07
IL295626A (en) 2022-10-01
KR20220148846A (ko) 2022-11-07
AU2021225491A1 (en) 2022-10-20
CN115279374A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
TWI831916B (zh) 包含tno155和瑞博西尼之藥物組合
TW202146021A (zh) 包含達拉菲尼、erk抑制劑和shp2抑制劑之三重藥物組合
WO2013139724A1 (fr) Polythérapie (vémurafenib et un inhibiteur de mdm2) pour le traitement de troubles prolifératifs
TW202313041A (zh) 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
US20210300921A1 (en) Ep4 inhibitors and synthesis thereof
US20220323436A1 (en) Protein kinase c inhibitors for treatment of uveal melanoma
CN114072205A (zh) 用tie-2激活剂治疗高血压的方法
TW202146024A (zh) 包含達拉菲尼、erk抑制劑和raf抑制劑或pd-1抑制劑之三重藥物組合
CN111936141A (zh) 包含达拉菲尼、曲美替尼和erk抑制剂的三重药物组合
AU2021260982B2 (en) Dosing regimen for treating a disease modulated by CSF-1R
WO2023204259A1 (fr) Produit pharmaceutique pour le traitement ou la prévention du cancer
AU2020351324B2 (en) Use of an MDM2 inhibitor for the treatment of myelofibrosis